Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation

OBJECTIVE - Humalog Mix25 is a manufactured premixed insulin formulation co ntaining insulin lispro and a novel insulin lispro-protamine formulation (N PL) in a ratio of 25.75%. The objective of this study was to compare Humalo g Mix25 to human insulin 30/70 (30% regular insulin/70% NPH) with respect t o glycemic control. RESEARCH DESIGN AND METHODS - Humalog Mix25 was compared with human insulin 30/70 in 89 individuals with type 2 diabetes during a 6-month randomized o pen-label two-period crossover study. Each insulin was administered twice d aily, before the morning and evening meals. Information regarding self-moni tored blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symp toms or BG less than or equal to 3.0 mmol/l), insulin dose, and HbA(1c) was collected. RESULTS - Treatment with Humalog Mix25 resulted in better postprandial glyc emic control after the morning and evening meals compared with treatment wi th human insulin 30/70. Overall glycemic control and the incidence of hypog lycemia were comparable between the treatments. CONCLUSIONS - In comparison to treatment with human insulin 30/70, twice da ily administration of Humalog Mix25 resulted in improved postprandial glyce mic control, similar overall glycemic control, and the convenience of dosin g immediately before meals.